This report explores the rapid advancement of targeted protein degraders as a high-potential modality, including trends, challenges, and leading biotech innovators.

Key takeaways:

Strong deal activity and investment momentum
Six innovative biotech leaders identified
Broad applications across multiple disease areas
Key innovation drivers include PROTACs, molecular glues, and AI
Ongoing challenges in clinical translation and regulation
Importance of differentiation and strong IP

Download the Report

Job function *

Please check this box to receive electronic communications from Clarivate about services, events, resources and offers you may find of interest. Clarivate will use your personal data to provide you with targeted communications, including via third-party sites, which may involve providing your (hashed) data to our partners. You acknowledge that your data may be processed in countries outside your residence, such as the United States. You can withdraw your consent anytime, including by unsubscribing from our mailing list. Further details can be found in our Privacy Notice.

By submitting this form, I understand my information will be processed in accordance with the Privacy Notice.